

Implementing an 'Alert of the Month' across Interventional Procedural/Non-OR Units to Improve Patient Safety

Sheila Barnett M.D., Julia Sheehan, and Catherine Annas, J.D.

Beth Israel Deaconess Medical Center, Boston MA

Introduction/Problem

The RL6 Safety Reporting System collects adverse events reported by staff, including events in interventional procedure areas. An idea for an 'Alert of the Month' for interventional procedural/non-OR areas was created to help the units spot any recurring incidents that may be appearing in their area as well as remind departments of current protocols and procedures.

The team plans to distribute electronic alerts of select incidents to the directors/managers of each unit for educational purposes. By administering these electronic alerts, it will help to inform clinicians in procedural departments and hopefully improve quality of safety practices throughout all units.

Alert of the Month – Example

	200117	LIKE, SOUNI	7 121112 (21 10)	Risk Reduction Strategies
LASA medications are de	fined as medications with similar ap	pearing names and/or packaging, or n	nedications with similar	1.Barcode Scanning 2. Stock segregation
sounding names. These m	edications have the potential for ca	using errors from inadvertent intercha	nge of these medications.	5. Yallman lettering 4. Order sets or alerts
emphotericin 8 deoxycholate	CloMDine	HumaLOG Mix 75/25	Metoproloi Tartrate (Lopressor)	RiTUKimab
Amphotericin B Liposomal	CLonacePAM	HumsLIN 70/30	Metoproidi Succinate (Togral X1)	OBINUtuoumab
(Ambisome)				OFAturnamab
	CycloPHOSPHAMIDE 25mg tab	HumpLIN	Morphine Solution 2 reg/ml.	ALEMeuzumab
MiLoride	CycloSPORINE modified (Neoral)	HumoUN R U-500	Concentrated Morphine solution 20 mg/ml.	
ant.00Pine	25mg cap	NovoLIN		Sodium Chloride 0.45% flush 3mL
	CycloSPORINE (Sandimmune) 25mg		NCARdgine	Sodium CITRATE 4% flush 3mL
Aftipiprazole	сар	HydrOKfaine	NFEdgine	
Omegrazeie		HydALAZINE	NMODipine	Solu-CORTEF (hydrocortisone sodium suc
	DASatinib			Solu-MEDROL (methylprednisolone sodiu
specificine	Imatinib	HYD#Ocodone	OLANZapine intrarruscular (Zyprena)	cinate)
Azarthioprine		ewyC0000NE	OLANZapine ER Inj Susp (Zyprexa Retprevv)	Depo-Medrol (methylpredissolone acetal
57/	Depakote ER (extended release)			
BuPFIOPion XI, (daily)	Depakote (delayed release)	H/DROmorphone	OxyCODONE Seng	SUMADIAZINE
BuPROPion SR [twice daily]		Morphine	DoyCODONE SR (DxyCONTIN) 10mg	SulfaSALAzine
	Depo-Provera			SWMSCHAZOLE
BR/VAracetare	[medrovyprogesterone acetate]	InFL/Kimab	PACItaxel (TaxOL)	
LEVETiracetam	Depo-Medrol	R/TU/Kimab	DOCEtaxel (Taxe/TERE)	Tacrolimus 0.5 mg
	(methy/prednisolone scetate)	***************************************	Process (Pro-proj	Tacrolimus 5 mg
bsoFifone		LACOrarride	PENTobarbital	
tuPFOPien	Dimentry CRIMATE	LOPERamine	PHENobarbital	Td (tetanus, dightheria)
	DiphenhydriAMINE	tor to a to a	The second	Tdap (tetanus, diphtheria, acellular pertu
CarliAMazepine	o geomy control	LamiNUDINE	Presmococcal 15-valent conjugate vaccine	DTaP (digitatheria, tetanus, aceilular pertu
Olicarbacepine	DOXOrubida	LarnoTRiging	(Prevent 13)	primary vaccination series)
	DAUMOrubida	Campringing	Preumococcal 7-valent conjugate vaccine	primary reconstruction person
Carbidope-Levodope OOT	IDArubicin	LarsoTRigine	(PCV7)	TOLAZamide
Carbidopa-Levodopa R	TOPE GOLDE	LevET/RAcetam	Pneumococcai polytacdtaride vaccine	TOUBUTamide
Carbidopa-Levodopa CR	Doxycycline 100mg	Levis I IIO-Certain		TOCAD LANGE
Carrioty Cerroliya Cr.	DICYCLOMine 200mg	Look and automate	(Pneumovaii 23)	TreMADel
CARBOplatin	Dicretonne soong	Lanthamum carbonate	PEMBROLoursab	
	DULguetine	Lithium carbonate		Tra200ene
CiSplatin			PALMizumab	*
	FLUcketine	Construction of the Construction	PANitumumab	Trasticurvab
CeFAZolin CefTRIAXone	PAffoxetine	Liposomai DOHOrubicia (DoXIL)		Ado-tractuounab entancine
Certificocene	01-700	Liposomai DAUNOrubicin DaunoKome	PredniSONE	and the second second
	GIp(2)DE		PrednisoLONE	ValACYdovir (ValTREX)
CeleBREX	GYBURICE	Lymphocyte immune globulin (ATGAM)	2	ValGANoclovir (ValCYTE)
CereBYX		Anti-Thyrnocyte (rabbit)(Thyrnoglobulin)	QsiNDine	
CeleRA	Guaf ENegin	(ATG)	QuININE	Ventafavine IR (immediate release)
	OuenFACINE			Ventafavine ER (extended releace)
CycloSERINE		MesFORMIN	PETROVY	
CycloSPORINE	Heparin (25,000 units/250mL)	MetroMOAZOLE	RITONAutr	VinBLAStine (Velban)
	Hespan			VinCRIStine (Oncovin)
ChlordispePOKDE		Methimacole	Rifampin	
ChiorproMAZINE	HumaLOG	Metolacone	Pifavirnin	
Chlomen#4ASIC#	Neural CVS			

Image above depicts list of look-alike and sound-alike medications that are used in the pharmacy and procedural units to differentiate between similar medications. Appendix List for Policy #:03-07-05 Look-Alike Sound –Alike Error Prevention (Pharmacy Department).

Aim/Goal

By implementing a monthly alerting system of common adverse events that occurred in a procedural/non-OR unit, it will help to increase alertness in different departmental units, help to improve reporting of any unfavorable events, and help to refresh clinicians of safety protocols/procedures put in place. This project was funded by the CRICO Ambulatory Safety Grant-Centralized Oversight of Interventional Procedure Safety and discussed with the Interventional Procedures Committee

The Team

- Sheila Ryan Barnett M.D.-Anesthesia
- Sugantha Sundar M.D.-Anesthesia (Committee Chair) and Interventional Procedures Committee
- Julia Sheehan-Health Care Quality
- Catherine Annas J.D.-Health Care Quality

The Interventions

- Observed and collected adverse events in the RL6 Safety Reporting System in procedural/non-OR units
- Noticed severity level trends in certain adverse event types in different procedural/non-OR units
- Developed an 'Alert of the Month' handout for procedural/non-OR areas to discuss adverse events that could potentially occur in their unit
- Presented and discussed at both the CRICO IP Safety Project Meeting and Interventional **Procedures Committee**

For more information, contact:

Julia Sheehan, Research Data Coordinator / jsheeha6@bidmc.harvard.edu







Implementing an 'Alert of the Month' across Interventional Procedural/Non-OR Units to Improve Patient Safety

Sheila Barnett M.D., Julia Sheehan, and Catherine Annas J.D.

Beth Israel Deaconess Medical Center, Boston MA

Results/Progress to Date






Image above shows example of format type for 'Alert of Month' to be sent to different procedural/non-OR departments. This example alert discussed lookalike and sound-alike medications from the Omnicell and Pharmacy. Included is a picture of what a typical Omnicell looks like.

Error Reduction Strategies for Look-alike and Sound-alike Medications

- Prescribing dose limits
- Standardized drug concentrations
- Stock segregation
- Bar-coding and scanning
- Tall-man lettering

List above states five error reducing strategies when dealing with look-alike/sound-alike medications from Pharmacy. Policy #:03-07-05 Look-Alike Sound -Alike Error Prevention (Pharmacy Department).

Lessons Learned

- Underreporting of adverse events in procedural/non-OR areas
- Clinicians not compliant with protocols of RL6 reporting/do not understand what RL6 is
- Comprehensive safety of adverse event siloed in procedural/non-OR departments makes it harder to track for reporting purposes

Next Steps

- Continue to monitor adverse events reported into RL6 Safety System and update procedural departments of any common trends that occur
- Email 'Alert of Month' to directors of procedural/non-OR units to administer within department
- Monthly emails will be sent out to procedural/non-OR area staff members to keep them informed of incidents occurring in similar units
- Further educate clinical staff in other common adverse event types and help reinforce standard protocols put in place for safety measures
- Discussion for potential rewards or quizzes to help refresh clinicians of procedures/protocols put in place for procedural/non-OR areas
- Potentially spreading idea of 'Alert of Month' to non-procedural areas with similar interconnection as procedural/non OR units for patient safety and compliance

For more information, contact:

Julia Sheehan, Research Data Coordinator / jsheeha6@bidmc.harvard.edu